Phase Ⅱ Clinical Study of R435 (Bevacizumab) in Combination With Paclitaxel in Patients With Inoperable Metastatic Breast Cancer

You may be eligible if

• At least 20 years old and obtained a written informed consent
• Advanced breast cancer (StageⅣ) or Inoperable metastatic breast cancer
• HER2 negative
• At least one measurable lesion based on RECIST criteria
• No previous chemotherapy for metastatic breast cancer